

参考文献 (続き)

- Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel. *JAMA*. 2020;324(16):1651-1669.
- Saladini F, Giannini A, Boccuto A, et al. Comparable In Vitro Activities of Second-Generation HIV-1 | Integrase Strand Transfer Inhibitors (INSTIs) on HIV-1 Clinical Isolates with INSTI Resistance Mutations. *Antimicrob Agents Chemother*. 2019;64:e01717-19.
- Santoro MM, Fornabaio C, Malena M, et al. Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen. *Int J Antimicrob Agents*. 2020;106027.
- Sax PE, Rockstroh JK, Luetkemeyer AF, et al. Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV. *Clin Infect Dis*. 2020;ciaa988. [Online ahead of print]
- Scherrer AU, von Wyl V, Yan W, et al. Emergence of acquired HIV-1 drug resistance almost stopped in Switzerland: A 15-year prospective cohort analysis. *Clin Infect Dis*. 2016;62(10):1310-1317.
- Segal-Maurer S, Castagana A, Berhe M, et al. Potent antiviral activity of lenacapavir in Phase 2/3 in heavily ART-experienced PWH. CROI 2021. Abstract 127.
- Shafer RW, Hertogs K, Zolopa AR, et al. High degree of interlaboratory reproducibility of Human Immunodeficiency Virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. *J Clin Microbiology*. 2001;39:1522-1529.
- Stanford University HIV Drug Resistance Database. Available at: <https://hivdb.stanford.edu>. Accessed July 14, 2020.
- Sterrantino G, Borghi V, Callegaro AP, et al. Prevalence of predicted resistance to doravirine in HIV-1 positive patients after exposure to non-nucleoside reverse transcriptase inhibitors. *Int J Antimicrob Agents*. 2019;53(4):515-519.
- Talbot A, Grant P, Taylor J, et al. Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: An independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors. *Antimicrob Agents Chemother*. 2010;54:2473-2479.
- Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: The Havana trial. *AIDS*. VancerVeen L, et al. *AIDS* 2022. Abstract EPB239
- Vingerhoets J, Tambuyzer L, Azijn H, et al. Resistance profile of etravirine: Combined analysis of baseline genotypic and phenotypic data from the randomized, controlled phase III clinical studies. *AIDS*. 2010;24:503-514.